Research and Markets: The Pharmaceutical Market: USA

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/dd5524/the_pharmaceutical) has announced the addition of the "The Pharmaceutical Market: USA" report to their offering.

THE PHARMACEUTICAL MARKET: USA - REVIEW

In November 2010, the Republicans took control of the House of Representatives, whilst the Democrats retained control of the Senate, with a reduced majority. These results will complicate Barack Obama's presidency for the remaining two years, following the approval of a major healthcare reform in March 2010. The National Commission on Fiscal Responsibility & Reform published its first draft document in November 2010. Medium-term proposals affecting the health sector include paying doctors and other providers less, increasing drug rebates and strengthening the Independent Payment Advisory Board (IPAB); the latter two measures could affect the pharmaceutical industry particularly. The main long-term proposal affecting the health sector is to contain growth in total federal health spending to GDP+1% after 2020.

The effect of the healthcare reform will be difficult to measure but pharmaceutical sales are expected to be boosted in the long-term. R&D investments are large but growth has slowed down. Around 85.0% of the USA's pharmaceutical requirements are domestically manufactured. A number of companies have made significant cutbacks, making reductions to sales forces. There have been a number of plant closures and scaling back of investment plans. For companies traditionally reliant on chemical drugs, there is an increasing interest in moving into the biologic field. This is seen as more lucrative as it has greater scope for the development of innovative products and is less susceptible to generic competition. Pfizer and Merck have diversified and entered the biologic sector, whilst Roche has specialised in biologics and diagnostics.

The OTC and generic sectors continue to attract domestic and foreign interest. The OTC sector is expected to increase by a low CAGR between 2010 and 2015, but it remains attractive and market concentration continues. In March 2010, sanofi-aventis completed the acquisition of Chattem, creating the world's fifth-largest consumer healthcare company. Shaped by the Hatch Waxman legislation of 1984, generics are usually far cheaper than branded drugs, with the advent of generic competition leading to rapid price falls. The sector is expected to increase by a moderate CAGR between 2010 and 2015. Major developments in the sector between September and November 2010 include Impaxs litigation against Shire; Watsons agreement with Ortho-McNeil; Hikmas acquisition of Baxters US generic injectables business; Endos agreement to acquire Qualitest; Elites licence/manufacturing/supply agreement; and Mylans complete acquisition of Bioniche.

The US FDA held a two-day public hearing on biosimilars in November 2010, following the passage of the Biologics Price Competition & Innovation (BPCI) Act in March 2010. The Act amends section 351 of the Public Health Service Act (PHSA) to allow for the application of a biologic product as biosimilar or interchangeable. Brand-name producers are the winners, as biosimilar competition has been restricted by implementing a 12-year data exclusivity period. Major developments in the sector between September and November 2010 include Baxters acquisition of Archemixs haemophilia-related assets; Neopharms merger with INSYS; Kadmons acquisition of Three Rivers; Emergents acquisition of Trubion; Pfizers agreement to sell Biocons insulin biosimilars; Celgenes acquisition of Abraxis; BMS acquisition of Zymogenetics; sanofi-aventis offer to acquire Genzyme, which has been rejected; and sanofi-Pasteurs acquisition of Vaxdesign.

ENHANCED STRATEGIC INTELLIGENCE

These highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:

  • Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.
  • Specialised intelligence on OTCs, generics, biologics and biosimilars.
  • Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.
  • A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.

The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis. HEALTHCARE STATISTICS

A comprehensive tabula review, comprising demographics, epidemiology, health expenditure, hospital and primary care infrastructure & services and healthcare personnel, is additionally included.

Key Topics Covered:

  • HIGHLY DETAILED REPORT CONTENT
  • EXECUTIVE SUMMARY
  • MACROENVIRONMENT
  • EPIDEMIOLOGY
  • HEALTHCARE
  • REGULATORY AFFAIRS
  • PRICING & REIMBURSEMENT
  • DISTRIBUTION CHANNELS
  • MARKET ANALYSIS
  • COMPETITION
  • OTC PHARMACEUTICALS
  • GENERIC PHARMACEUTICALS
  • BIOLOGICS & BIOSIMILARS
  • OPPORTUNITIES & CHALLENGES
  • DIRECTORY
  • METHODOLOGY & SOURCES

For more information visit http://www.researchandmarkets.com/research/dd5524/the_pharmaceutical

Source: Espicom Business Intelligence Ltd



CONTACT:

Research and Markets
Laura Wood, Senior Manager,
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KEYWORDS:   United States  North America

INDUSTRY KEYWORDS:   Health  Pharmaceutical  FDA

MEDIA:

Logo
 Logo

Suggested Articles

In an era of limited access to key decision makers, how are you mobilizing your field force to communicate the value of your brands and real-world evidence?

Novo Nordisk’s Ozempic is off to a blazing start, and the company just threw more fuel on the fire with a pair of trial wins.

Biosims to Roche's Big 3 cancer drugs will chisel out a $10 billion sales gap by 2023, but newer meds could chip in $16.3 billion, the drugmaker says.